62
Views
5
CrossRef citations to date
0
Altmetric
Original Research

A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery

, , , , &
Pages 1243-1255 | Published online: 24 Mar 2016
 

Abstract

Introduction

Hepatocellular carcinoma is currently the second leading cause of cancer-related deaths worldwide with an increasing incidence.

Objective

The objective of this study is to investigate the effect of vascular endothelial growth factor small interfering RNA (VEGF-siRNA) on rabbit VX2 carcinoma cell viability in vitro and the effect of transarterial embolization (TAE)-mediated VEGF-siRNA delivery on the growth of rabbit VX2 liver-transplanted model in vivo.

Methods

Quantitative reverse transcription polymerase chain reaction, enzyme-linked immunosorbent assay, and Western blot technologies were used to detect the expression level of VEGF. TAE and computed tomography scan were used to deliver the VEGF-siRNA and detect the tumor volume in vivo, respectively. Microvessel density was detected by immunohistochemistry with CD34 antibody. A biochemical autoanalyzer was used to evaluate the hepatic and renal toxicity.

Results

The designed VEGF-siRNAs could effectively decrease the expression levels of VEGF mRNA and protein in vitro and in vivo. In vitro, the viability of rabbit VX2 carcinoma cells was reduced by 38.5%±7.3% (VEGF-siRNA no 1) and 30.0%±5.8% (VEGF-siRNA no 3) at 48 hours after transfection. Moreover, in rabbit VX2 liver-transplanted model, the growth ratios of tumors at 28 days after TAE-mediated siRNA delivery were 155.18%±19.42% in the control group, 79.67%±19.63% in the low-dose group, and 36.09%±15.73% in the high-dose group, with significant differences among these three groups. Microvessel density dropped to 34.22±4.01 and 22.63±4.07 in the low-dose group and high-dose group, respectively, compared with the control group (57.88±5.67), with significant differences among these three groups. Furthermore, inoculation of VX2 tumor into the liver itself at later stage induced significant increase in alanine aminotransferase and aspartate aminotransferase, indicating an obvious damage of liver functions, while treatment of VX2 tumor via TAE-mediated VEGF-siRNA had no toxicity to the livers and kidneys of rabbits, and VEGF-siRNA had the ability to protect liver damage induced by tumor growth.

Conclusion

This is the first study to demonstrate that targeting VEGF via TAE-mediated siRNA delivery may become a powerful new option for effective treatment of hepatocellular carcinoma in the clinic.

Supplementary material

Figure S1 Optimization experiment of transfection efficiency for siRNA using FAM-scr-siRNA.

Notes: VX2 cells were transduced in a 12-well format with FAM-scr-siRNA at the concentrations of 10 nM, 20 nM, and 50 nM for 48 hours. Blue fluorescence of DAPI and green fluorescence of FAM-scr-siRNA are shown.
Abbreviations: siRNA, small interfering RNA; DAPI, 4′,6-diamidino-2-phenylindole.
Figure S1 Optimization experiment of transfection efficiency for siRNA using FAM-scr-siRNA.

Acknowledgments

This project was supported by Scientific Research Fund of Zhejiang Provincial Education Department (no Y201225858) and Natural Science Foundation of Zhejiang Province (no Y2110172). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors contributions

Zou Y, Fu C-Y, and Zhang M-M initiated the study, performed experiments, analyzed the data, and drafted the manuscript. Guo C-G, Yang Z-G, and Sun J-H conducted the in vitro analyses. Zou Y and Fu C-Y critically revised the manuscript. Zou Y and Fu C-Y supervised the project, advised with regard to the experimental design, and edited the manuscript. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.